Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients

KA Attia, KC Ackoundou-N’guessan, AT N’dri-yoman, AK Mahassadi, E Messou, YF Bathaix, YH Kissi

Abstract
AIM: To compare the performance of the Child-Pugh-Turcott (CPT) score to that of the model for end-stage liver disease (MELD) score in predicting survival of a retrospective cohort of 172 Black African patients with cirrhosis on a short and mid-term basis.

METHODS: Univariate and multivariate (Cox model) analyses were used to identify factors related to mortality. Relationship between the two scores was appreciated by calculating the correlation coefficient. The Kaplan Meier method and the log rank test were used to elaborate and compare survival respectively. The Areas Under the Curves were used to compare the performance between scores at 3, 6 and 12 mo.

RESULTS: The study population comprised 172 patients, of which 68.9% were male. The mean age of the patient was 47.5 ± 13 years. Hepatitis B virus infection was the cause of cirrhosis in 70% of the cases. The overall mortality was 31.4% over 11 years of follow up. Independent factors significantly associated with mortality were: CPT score (HR = 3.3, 95% CI [1.7-6.2]) (P < 0.001) (stage C vs stage A-B); Serum creatine (HR = 2.5, 95% CI [1.4-4.3]) (P = 0.001) (Serum creatine > 1.5 mg/dL versus serum creatine < 1.5 mg/dL); MELD score (HR = 2.9, 95% CI [1.63-5.21]) (P < 0.001) (MELD > 21 vs MELD < 21). The area under the curves (AUC) that predict survival was 0.72 and 0.75 at 3 mo (P = 0.68), 0.64 and 0.62 at 6 mo (P = 0.67), 0.69 and 0.64 at 12 mo (P = 0.38) respectively for the CPT score and the MELD score.

CONCLUSION: The CPT score displays the same prognostic significance as does the MELD score in black African patients with cirrhosis. Moreover, its handling appears less cumbersome in clinical practice as compared to the latter.

© 2008 WJG. All rights reserved.

Key words: Model for end-stage liver disease score; Child score; Cirrhosis; Black African; Survival

http://dx.doi.org/10.3748/wjg.14.286

Attia KA, Ackoundou-N’guessan KC, N’dri-yoman AT, Mahassadi AK, Messou E, Bathaix YF, Kissi YH. Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. World J Gastroenterol 2008; 14(2): 286-291

INTRODUCTION
The Child-Pugh-Turcotte (CPT) score has usually been used to assess the prognosis of patients with cirrhosis\(^1\), since it is related to the severity of the liver disease.

The detrimental effect of renal failure on survival of patients with cirrhosis is widely acknowledged\(^2-6\). The prevalence of renal failure in cirrhotic patients varied between 7%-65%\(^7-9\). About 20% of the cirrhotic patients presenting with ascites were likely to display an acute pre-renal failure. This value has been reported to exceed 50% when end-stage liver disease is present\(^10\).

The model for end-stage liver disease (MELD) score has recently been developed to better rationalize liver graft allocation. Indeed liver graft allocation has been so far performed according to the severity of the liver failure as determined by the CPT score plus the time spent on the waiting list. Since the first transplanted have almost been the first on the waiting list and knowing that they did not necessary display the most severe disease, such an approach has been subjected to debate\(^11,17\). The MELD score has been elaborated using three independent prognostic factors: creatine, International Normalized Ratio (INR) and bilirubin. In a study in 311 patients on the waiting list, the MELD score has been found adequate to predict mortality\(^12,20\). The MELD score has been thus far used in the USA for liver graft allocation in place of the CPT score.
Several studies have been performed to compare the performance of the two scores in predicting survival in patients with cirrhosis\(^{[21-33]}\). However such studies have yielded conflicting results\(^{[23, 24, 28, 30-33]}\).

The aim of the present study was to compare the performance of the MELD score to that of the CPT score to predict survival in a retrospective cohort of 172 black African patients with cirrhosis.

**MATERIALS AND METHODS**

**Type of study**
A retrospective analysis of a cohort of black African patients with cirrhosis has been undertaken. Patients have been recruited from January 1, 1991 to December 31, 2001 (11 years) at the hepatology unit of the University hospital of Yopougon (Abidjan), one of the three tertiaries hospitals of the capital, admitting and hospitalising at least 650 patients a year for a total capacity of 20 beds.

**Patients**
In our daily practice, all the patients who were diagnosed as having cirrhosis were systematically hospitalised, because most of them were seen at a very late stage of the disease. Of 307 patients recruited over this study period, 135 have been excluded because of missing data. 172 patients have, therefore, been considered for analysis.

**Methods**
Data of the patients such as, age, gender, motives of admission, aetiology of cirrhosis, serum creatine, CPT score and the MELD score, date of first symptoms of decompensated cirrhosis, date of first admission, date of last visit for the patients lost to follow up or still alive, the date of death for deceased patients have been all collected using a standardized collection sheet.

**Definitions**
The CPT score has been widely described elsewhere. It has been elaborated by using five (5) parameters: hepatic encephalopathy, ascite, prothrombin in percentage, serum albumin in g/L and bilirubin in mg/L.

The MELD score: It has been elaborated by using the Malinchoc formula which comprises 3 parameters: INR, bilirubin (mg/dL) and creatine (mg/dL). This formula is as follow: \[9.57 \times \text{Loge creatine (mg/dL)} + 3.78 \times \text{Loge bilirubin (mg/dL)} + 11.20 \times \text{Loge INR} + 6.43\].

Time of follow up: It corresponds to the time between the date of first admission for cirrhosis and the date of last visit or the date of death for deceased patients.

Time of survival: It corresponds to the time between the date of the first symptoms of decompensated cirrhosis as reported by the patient and the date of last visit for the patients lost to follow up or still alive or the date of death for the deceased patients.

**Statistical analysis**
By univariate analysis, relationship between mortality and the following parameters has been assessed: age, gender, aetiology of cirrhosis, serum creatine, CPT score and the MELD score. The Student t-test or the Mann-Whitney test was used for quantitative parameters and the chi square test or the Fischer exact test for qualitative parameters. A multivariate analysis has been performed using a Cox model in a forward selection manner. Two models have been elaborated subsequently: the first has included all the parameters used in the univariate analysis with the exception of serum creatine. The second model has included all the parameters used in the univariate analysis at the exception of the MELD score. Survival has been elaborated using the Kaplan Meier method. The log rank test has been used for comparison of survival between groups. Correlation between the two scores has been evaluated. The ROC curve has been used to compare performance between scores.

**RESULTS**
The different motives of admission of patients with cirrhosis were: ascites and oedema of the lower limbs (68.6%), jaundice (25.2%), haemorrhage of the digestive tract (15.1%) and hepatic encephalopathy. The study population comprised 172 patients, of which 69.8% were male. The mean age of the patients was 47.5 ± 13.54 years. 57% of the patients were with a CPT score stage C, 23.3% had renal failure and the mean MELD score was 20.9 ± 10.87. Hepatitis B was the main cause of cirrhosis in 45.3% of the case (Table 1). Over the study period (11 years), 54 out of 172 patients (31.4%) have died, of which 22 during the first three months and 32 the first 6 mo. The median and the mean duration of follow up were 206 and 226.6 ± 41.6 d, respectively. By univariate analysis, the following parameters have appeared to significantly influence mortality: age > 48 years old (P < 0.023); male gender (P < 0.003); CPT score stage C (P < 0.016); serum creatine > 1.5 mg/dL (P < 0.001) and MELD score over 21 (P < 0.03). Indeed, the mean CPT score has appeared significantly less elevated in living cirrhotics as compared to those who have died during the study period (10.2 ± 0.28 vs 11.3 ± 0.33, respectively; P = 0.02), as it was with the MELD score (19.4 ± 0.83 vs 24.2 ± 1.85, P = 0.007, respectively). Moreover mortality increased proportionally to the level

| Table 1 Characteristics of the study population |
|-----------------------------------------------|
| Male (%)                                      | 120/172 (69.8) |
| Mean age (yr)                                 | 47.5 ± 13.54   |
| Child-Pugh-Turcott score (%)                  |                |
| A                                            | 20 (11.6)      |
| B                                            | 54 (31.4)      |
| C                                            | 98 (57)        |
| Serum creatine (mg/dL) (%) < 1.5              | 132 (76.7)     |
| > 1.5                                         | 40 (23.3)      |
| MELD score (mean ± SD)                        | 20.9 ± 10.87   |
| MELD: Median (extreme)                        | 19.5 [6-66]    |
| Etiology (%)                                  |                |
| Virus B                                       | 78 (45.3)      |
| Virus C                                       | 17 (10)        |
| Both alcohol and virus B or C                 | 41 (23.8)      |
| Unknown                                       | 36 (20.9)      |

www.wignet.com
Table 2  Relationship between mortality and parameters

| Parameters          | Univariate analysis (Death (%)) | Multivariate analysis (Hazard ratio (95% CI); P) |
|---------------------|---------------------------------|-----------------------------------------------|
| Age (yr)            |                                 |                                               |
| ≤ 48                | 23.90                           | 0.023                                         |
| > 48                | 40.00                           |                                               |
| Gender              |                                 |                                               |
| Female              | 15.40                           | 0.003                                         |
| Male                | 38.30                           | 1.8 [0.96 - 3.24]; P = 0.07                   |
| Child-Pugh-Turcott  |                                 |                                               |
| A-B                 | 21.60                           | 0.016                                         |
| C                   | 38.80                           | 3.3 [1.7 - 6.2]; P < 0.001                    |
| Serum creatine (mg/dL) |                                 |                                               |
| ≤ 1.5               | 24.20                           | < 0.001                                       |
| > 1.5               | 55.00                           | 2.5 [1.4 - 4.3]; P = 0.001                    |
| MELD                 |                                 |                                               |
| ≤ 21                | 25.50                           | 0.030                                         |
| > 21                | 41.90                           | 2.9 [1.63 - 5.21]; P < 0.001                  |
| Aetiology           |                                 |                                               |
| Virus B or C        | 32.90                           | 0.670                                         |
| Both alcohol and virus | 40.20                           |                                               |
| Unknown             | 36.80                           |                                               |

1Median age; 2Through value of the MELD score significantly associated with mortality; 3Aetiology both virus and alcohol.

Figure 1 Survival according to the CPT score.

Figure 2 Survival according to the MELD score. *Through value of the MELD score significantly associated with mortality.

Table 3  Stepwise evaluation to find out the optimal cutoff point for both CPT and MELD score (%)

| CPT score | Sensitivity | Specificity | Positive predictive value | Negative predictive value |
|-----------|-------------|-------------|---------------------------|---------------------------|
| 8         | 96.30       | 20.30       | 35.60                     | 92.30                     |
| 9         | 74.00       | 33.00       | 33.60                     | 73.60                     |
| 10        | 70.40       | 49.20       | 38.80                     | 78.40                     |
| 11        | 66.70       | 52.60       | 39.10                     | 77.50                     |
| 12        | 59.30       | 57.60       | 39.00                     | 76.50                     |

| MELD score | Sensitivity | Specificity | Positive predictive value | Negative predictive value |
|-----------|-------------|-------------|---------------------------|---------------------------|
| 19        | 55.60       | 52.50       | 34.90                     | 72.10                     |
| 20        | 55.60       | 57.60       | 37.50                     | 73.90                     |
| 21        | 48.20       | 69.50       | 41.20                     | 74.60                     |
| 22        | 44.00       | 69.50       | 40.00                     | 73.70                     |
| 23        | 44.40       | 76.30       | 46.20                     | 75.00                     |

*Optimal cutoff point for CPT (Child-Pugh-Turcott) score; †Optimal cutoff point for MELD (Model for End-stage Liver Disease) score.

The overall survival at 3, 6 and 12 mo was 85.4% (95% CI: 78.5-90.1), 76.1% (95% CI: 67.7-82.6) and 67% (95% CI: 57.3-75), respectively. The median and mean survival time were 142.6 and 318 + 45.1 d, respectively. When the CPT score was considered, survival at 1 year was just 52.1% for CPT score stage C as compared to CPT stage A-B which was over 85% (Figure 1). A MELD score over 21 was synonymous of 50% of survival at 1 year as compared to a MELD score less than 21 for which survival was about 80% (Figure 2). A cut off point of 10, corresponding to the very least value of the CPT score stage C, has been found optimal to predict sensitivity (74%), specificity (49.2%), positive predictive value (38.8%) and negative predictive value (78.4%). A cut off point of 21 for the MELD score has been found optimal to predict sensitivity (48.2%), specificity (69.5%), positive predictive value (41.9%) and negative predictive value (74.6%) (Table 3). However, when the performance of the two scores was
Table 4 Comparison between The Area Under the Curve (AUC) of the CPT score and the MELD score in predicting survival at 3, 6 mo

| Survival | Pronostic score | AUC (95% CI) | P    |
|----------|----------------|--------------|------|
| At 3 mo  | CPT            | 0.72 (0.64-0.80) | 0.68 |
| At 3 mo  | MELD           | 0.75 (0.62-0.88) | 0.67 |
| At 6 mo  | CPT            | 0.64 (0.54-0.74) | 0.67 |
| At 6 mo  | MELD           | 0.62 (0.49-0.74) | 0.67 |
| At 12 mo | CPT            | 0.69 (0.60-0.78) | 0.38 |
| At 12 mo | MELD           | 0.64 (0.53-0.75) | 0.38 |

CPT: Child-Pugh-Turcott; MELD: Model for End-stage liver disease.

Compared at 3, 6 and 12 mo, no significant difference could be found between them. Moreover, the correlation coefficient between the two scores was 0.57 (P < 0.001) (Table 4 and Figure 3).

**DISCUSSION**

About 60% of our patients have displayed a CPT score stage C that amounts to severe liver disease. Hepatitis B has been the main cause of cirrhosis in our study population. The main factors that have appeared to influence mortality were a CPT score stage C (with an optimal cutoff point of 10), renal failure that was present in 1/4 of the patients, and a MELD score over 21. The performances of the two scores were comparable.

Renal failure occurring in the setting of cirrhosis has widely been reported to represent an independent risk factor for mortality.[2-6] However, the CPT[1] score that has been used so far to appreciate prognosis in patients with cirrhosis does not take into account the renal function. This has led, therefore, to the elaboration of the MELD score which formula encompasses serum creatinine for the evaluation of survival in patients with cirrhosis[11]. The performance of the two scores has been compared in several studies with conflicting results: some studies[11,18,22,25-27,29] have showed superiority of the MELD score over the CPT score in predicting survival in patients on the transplantation waiting list or in patients awaiting Transjugular Intrahepatic Portosystemic Shunt (TIPS), or even in patients with acute alcoholic hepatitis, while others have found the two score to be comparable[11,14,18,20,23]. Indeed, in the study by Zhang et al[31], the area under the curve (AUC) was significantly more with the MELD score than the CPT score: 0.95, 0.85 and 0.83 for the MELD and 0.70, 0.66 and 0.61 for the CPT score (P < 0.05) at 3, 6 and 12 mo, respectively. In the study by Papatheodoridis et al[32] analysing a cohort of 102 decompensated cirrhotics, the AUC as determined by the MELD score was comparable to that of the CPT score in predicting survival at 3, 6, 12 mo: 0.79, 0.77, 0.78 and 0.79 for the MELD score and 0.73, 0.71, 0.68 and 0.70 for the CPT score. And a recent review paper by Cholongitas et al[33] has highlighted the lack of a clear cut superiority of the MELD score over the CPT score in predicting mortality of cirrhotic patients before and after liver transplantation.

The present study has showed that the two scores were also comparable as the AUC was: 0.75, 0.62, and 0.64 for the MELD score and 0.72, 0.64, 0.69 for the CPT score at 3, 6, and 12 mo, respectively. Moreover, the through value of the MELD score in our study confirms the fact that this value varies from one study to another as it was at 14, 17 and 18 in the Angermayr[24], Cestron[32] and Ferral[25] study, respectively. This could be attributed to the fact that most of our patients were admitted a very late stage of the disease, explaining an elevated mean and median MELD score. The retrospective nature of our study has led to the exclusion of many patients for missing data. Should these patients have been recruited, different findings as the one reported might have been found. However, the present findings could easily be extrapolated to any of our patients since the epidemiological profile of the 172 recruited patients represent the one currently encountered in our daily practice. Our study, which represents the only of its kind to be performed in black African patients with cirrhosis, appears to be of a great interest. Indeed, our population characteristics are quite different from what are currently reported in western countries since our patients are much younger with a diagnosis of cirrhosis made at a very late stage of the disease and hepatitis B being the main cause of cirrhosis. Moreover, the high prevalence of hepatitis B virus in an endemic country, like the Ivory Coast, is often responsible for contamination at birth and in infancy, leading to chronic hepatitis in 30%-50% (when contamination take place at infancy) to 90% (when contamination take place at birth) of the cases[34-48]. In addition, the prognosis of our patients is further aggravated by the fact that most of them are diagnosed as having cirrhosis at a very late stage of the disease for different reasons; lack of insurance coverage, delay in hospital visit because of financial problems or cultural considerations. Consequently, few interventions could be offered to these patients as liver transplantation or endoscopic and/or radiological treatments are not currently available in our country. Inversely, Hepatitis C virus and alcohol remain the main causes of cirrhosis in western countries[40-42]. Contamination by hepatitis C virus occurs in adult age and chronic hepatitis related to alcohol represents a disease of adult patient.

Patients with cirrhosis are diagnosed at a very late
stage of the disease. Consequently, mortality is elevated. Renal and liver failures represent independent risk factors of mortality. In the present study, the performance of the MELD score has appeared comparable to that of the CPT score which remains the primary tool to assess patients in the daily practice. The improvement in the MELD score predicting survival ability over the CPT score may necessitate the incorporation in its determination of several others factors such as age, and population characteristics to allow the universal utilizability of this equation. The present study has indeed suggested the impact of the population characteristics on the MELD score level. The use of the CPT score in association with serum creatine as proposed by Angermayer could also be currently performed in daily practice in order to also improve its predicting survival ability.

REFERENCES

1. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, William R. Transsection of the oesophagus for bleeding oesophageal varices. Brit J Surg 1973; 60: 646-649
2. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827
3. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37: 233-243
4. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654
5. Deschênes M, Dufresne MP, Bui B, Fenyes D, Spahr L, Roy L, Lafontagne M, Pomier-Layrargues G. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol 1999; 94: 1361-1365
6. Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, Valente U. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003; 50: 1753-1755
7. Crawford D, Endre Z, Axelsen R, Linch SV, Balderson GA, Strong RW, Fleming SJ, Powell LW. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 1992; 19: 339-344
8. Wong F, Blendis L. New challenge of hepatorenal syndrome: Prevention and treatment. Hepatology 2001; 34: 1242-1251
9. Arroyo V, Gines P, Gerbes AL. Definition and diagnosis criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-176
10. Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann Hepatol 2002; 1: 72-79
11. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Terborg PL. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871
12. Freeman RB Jr. Edwards E. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl 2000 Sep; 6: 543-552
13. Robert A, Chazoulières O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996; 24: 1392-1394
14. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Thorne TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2001; 33: 464-470
15. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RAF, Kim WR. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001 Jul; 7: 567-580
16. Mazzaferrro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ceccarelli L. Liver Transplant for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
17. Freeman RB, Rohrer RJ, Katz E, Lewis WD, Jenkins R, Cosimi AB, Delmonico F, Friedman A, Lorber M, O’Connor K, Bradley J. Preliminary results of a liver allocation plan using a continuous medical severity score that de-emphasizes waiting time. Liver Transpl 2001; 7: 173-179
18. Demeux N, Arnaudou S, Opas M. Measurement of intracellular Ca2+ concentration. Methods Cell Biol 2002; 70: 453-474
19. Trotter JF, Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 2004; 21: 1871-1874
20 Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. *Eur J Gastroenterol Hepatol* 2004; 16: 607-612.

21 Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. *BMJ Gastroenterol* 2002; 2: 2.

22 Salerno F, Merli M, Cazzaniga M, Valeriano V, Rossi P, Lovaria A, Meregaglia D, Niccolini A, Lubatti L, Riggio O. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. *J Hepatol* 2002; 36: 494-500.

23 Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, Testa E, Risso D, Colla G, Testa R. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: A European study. *Gut* 2003; 52: 134-139.

24 Angermayr B, Cejna M, Karmel F, Gschwantler M, Koenig F, Pedlch J, Mendel H, Pichler L, Wichlas M, Kreil A, Schmid M, Ferlitsch A, Lipinski E, Brunner H, Lammer J, Ferenci P, Gangl A, Peck-Radosavljevic M. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. *Gut* 2003; 52: 879-885.

25 Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA. Survival after elective transjugular intrahepatic portosystemic shunt creation: Prediction with model for end-stage liver disease score. *Radiology* 2004; 231: 231-236.

26 Giannini E, Botta F, Fumagalli A, Malfatti F, Testa E, Chiarbonello B, Polegato S, Bellotti M, Milazzo S, Borgonovo G, Testa R. Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score? *Liver Int* 2004; 24: 465-470.

27 Zhang JY, Zhang FK, Jia JD, Wang BE. Development of prognostic models of liver diseases. *Zhonghua Ganzangbing Za Zhi* 2005; 13: 867-877.

28 Papatheodoridis GV, Cholongitas E, Dimitriadou E, Touloumi G, Sebastiano V, Archimandritis AJ. MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. *World J Gastroenterol* 2005; 11: 3099-3104.

29 Feijar T, Saika V, Hulek P, Vanasek T, Krajina A, Jirkovsky V. MELD score in prediction of early mortality in patients suffering refractory ascites treated by TIPS. *Vnitr Lek* 2006; 52: 771-776.

30 Schroeder RA, Marroquin CE, ButeBP, Khuri S, Henderson WG, Kuo PC. Predictive Indices of Morbidity and Mortality after Liver Resection. *Ann Surg* 2006; 243: 373-379.

31 Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, Burroughs AK. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. *Liver Transpl* 2006; 12: 1049-1061.

32 Cesbron E, Tropet A, Bourrier J, Pillette C. La valeur prédictive de mortalité du score MELD est-elle supérieure à celle du score de Child-pugh et peut-être améliorée? Etude prospective chez 309 patients issus d’un centre hospitalier général. *Gastroenterol Clin Biol* 2006; 30: A98 (Abstract).

33 Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild HH, Sauerbruch T. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. *Am J Gastroenterol* 2003; 98: 1167-1174.

34 Martinson FE, Weigle KA, Royce RA, Weber DJ, Suchindram CM, Lemon SM. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. *Am J Epidemiol* 1998; 147: 478-487.

35 Abdool Karim SS, Thejpal R, Coovadia HM. Household clustering and intra-household transmission patterns of hepatitis B virus infection in South Africa. *Int J Epidemiol* 1991; 20: 495-503.

36 Whittle H, Inskip H, Bradley AK, McLaughlan K, Shenton F, Lamb W, Eccles J, Baker BA, Hall AJ. The pattern of childhood hepatitis B infection in two Gambian villages. *J Infect Dis* 1990; 161: 1112-1115.

37 Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. *J Hepatol* 2003; 39: S64-S69.

38 Beasley RP, Hwang LY, Lin CC, Stevens CE, Wang KY, Sun TS, Hsieh FJ, Szmuness W. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. *Lancet* 1981; 2: 388-393.

39 McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis* 1985; 151: 599-603.

40 Hoffmann CJ, Thiio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. *Lancet Infect Dis* 2007; 7: 402-409.

41 Freeman RR Jr. Is waiting time a measure of access to liver transplantation? Is shorter necessarily better? *Hepatology* 2007; 46: 602-603.

42 Membreno F, Baz AL, Pandula R, Walse R, Lau DT. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed. *Gastroenterol Hepatol* 2005; 20: 474-481.

S-Editor Zhu LH  L-Editor Rippe RA  E-Editor Li HY